Global Pharmaceuticals Awards Grant to Myasthenia Gravis Alliance

November 24, 2009

HAYWARD, Calif.--(BUSINESS WIRE)--Nov. 24, 2009-- Global Pharmaceuticals, the generic products division of Impax Laboratories, Inc. (NASDAQ: IPXL), today announced their cooperation in awarding a modest grant to Myasthenia Gravis Alliance, also known as Myasthenia Gravis Foundation of Greater New York, Inc., a 501(3)(c) non profit membership corporation, incorporated in the State of New York. A portion of the grant will fund The Alliance Fellowship for Myasthenia Gravis Research, at the University of California, Davis, under the direction of Dr. Robert Fairclough, Faculty Researcher/ Principal Investigator. The remainder of the grant will help defer the cost of The Circle News and other operating items.

Myasthenia Gravis is a chronic, sometimes fatal autoimmune neuromuscular disease in which communication between nerve and muscle is impaired, causing muscle fatigue. The disease is highly misdiagnosed. A neurologist is recommended for diagnosis. Global Pharmaceuticals is a leading distributor of pyridostigmine bromide, a key agent used in the treatment of Myasthenia Gravis.

Christopher Mengler, R.Ph., divisional president of Global Pharmaceuticals said: “We are pleased to assist the Myasthenia Gravis Alliance with a grant to further research and awareness of this disease. We recognize the need for research that will hopefully lead to improved quality of life and eventually result in a cure.”

“Our primary goal is to ensure that the proper and appropriate information is forwarded to our myasthenic patients as soon as they are diagnosed,” Executive Director, Debra Santulli-Barone declared, “since the first two years of diagnosis is crucial.”

Ms. Santulli-Barone continued: “I am so grateful to Global Pharmaceuticals for listening to our needs and providing a grant. This will give our members newfound hope. We can now launch a monthly MG Series Support Meeting to address topics such as, 'How to Deal with Your Spouse/Family While Living with MG, Cold Weather Tips, and, Your Options with Medication.'”

About Myasthenia Gravis Alliance

Myasthenia Gravis Alliance has been a staple in the myasthenic community for over 20 years. The charitable nonprofit organization was formed to serve patient needs, promote public awareness, provide support for patients, while continuing to fund research when possible.

Myasthenia Gravis Alliance; Myasthenia Gravis Foundation of Greater New York, Inc. ( meetings will be held at 61 Gramercy Park North, Ste. 605, New York, NY 10010. For further information, call Debra Santulli-Barone at (212) 533-7005.

About Impax Laboratories, Inc.

Impax Laboratories, Inc. is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Impax markets its generic products through its Global Pharmaceuticals division and markets its branded products through the Impax Pharmaceuticals division. Additionally, where strategically appropriate, Impax has developed marketing partnerships to fully leverage its technology platform. Impax Laboratories is headquartered in Hayward, California, and has a full range of capabilities in its Hayward and Philadelphia facilities. For more information, please visit the Company's Web site at:

Photos/Multimedia Gallery Available:

Source: Impax Laboratories, Inc.

Impax Laboratories, Inc.
Mark Donohue, Sr. Director Investor Relations
(215) 933-3526